Renal outcomes of sacubitril/valsartan compared with valsartan under triple whammy exposure in heart failure patients: A retrospective observational study

IF 2.1 4区 医学 Q2 UROLOGY & NEPHROLOGY
Nefrologia Pub Date : 2026-08-01 Epub Date: 2026-03-11 DOI:10.1016/j.nefro.2026.501530
Yusuke Nakazawa, Midori Nakamura, Yusuke Kashiwagi, Takashi Kawakubo
{"title":"Renal outcomes of sacubitril/valsartan compared with valsartan under triple whammy exposure in heart failure patients: A retrospective observational study","authors":"Yusuke Nakazawa,&nbsp;Midori Nakamura,&nbsp;Yusuke Kashiwagi,&nbsp;Takashi Kawakubo","doi":"10.1016/j.nefro.2026.501530","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The concurrent use of renin–angiotensin–aldosterone system (RAAS) inhibitors, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs), known as the “triple whammy (TW),” increases the risk of acute kidney injury (AKI). Sacubitril/valsartan has demonstrated favorable renal effects in heart failure populations; however, its impact under triple whammy exposure remains unclear.</div></div><div><h3>Methods</h3><div>This single-center retrospective observational study included patients with heart failure receiving valsartan or sacubitril/valsartan in combination with diuretics who were newly prescribed an NSAID between May 2013 and July 2024. Changes in serum creatinine (SCr) within 30 days after NSAID initiation were compared between groups. Multivariable linear regression was performed to identify determinants of relative SCr change. Factors associated with AKI, defined as an increase in SCr ≥0.3<!--> <!-->mg/dL, were evaluated using multivariable logistic regression with Firth's penalized likelihood method to address sparse event counts.</div></div><div><h3>Results</h3><div>A total of 168 patients were included (valsartan, <em>n</em> <!-->=<!--> <!-->71; sacubitril/valsartan, <em>n</em> <!-->=<!--> <!-->97). The sacubitril/valsartan group had a higher diuretic burden at baseline. Despite this, relative increases in SCr were significantly smaller compared with the valsartan group. In multivariable linear regression analysis, higher loop-diuretic-equivalent dose was independently associated with greater SCr elevation, whereas sacubitril/valsartan use was associated with smaller relative SCr increases. In Firth logistic regression analysis, higher loop-diuretic dose was independently associated with AKI, while sacubitril/valsartan use was not significantly associated with AKI.</div></div><div><h3>Conclusions</h3><div>Under triple whammy exposure, sacubitril/valsartan was associated with smaller early increases in SCr compared with valsartan, while diuretic intensity emerged as a consistent determinant of renal deterioration. Although causality cannot be established, these findings highlight the importance of volume management and support further prospective investigation.</div><div>.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 7","pages":"Article 501530"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nefrologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0211699526000470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The concurrent use of renin–angiotensin–aldosterone system (RAAS) inhibitors, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs), known as the “triple whammy (TW),” increases the risk of acute kidney injury (AKI). Sacubitril/valsartan has demonstrated favorable renal effects in heart failure populations; however, its impact under triple whammy exposure remains unclear.

Methods

This single-center retrospective observational study included patients with heart failure receiving valsartan or sacubitril/valsartan in combination with diuretics who were newly prescribed an NSAID between May 2013 and July 2024. Changes in serum creatinine (SCr) within 30 days after NSAID initiation were compared between groups. Multivariable linear regression was performed to identify determinants of relative SCr change. Factors associated with AKI, defined as an increase in SCr ≥0.3 mg/dL, were evaluated using multivariable logistic regression with Firth's penalized likelihood method to address sparse event counts.

Results

A total of 168 patients were included (valsartan, n = 71; sacubitril/valsartan, n = 97). The sacubitril/valsartan group had a higher diuretic burden at baseline. Despite this, relative increases in SCr were significantly smaller compared with the valsartan group. In multivariable linear regression analysis, higher loop-diuretic-equivalent dose was independently associated with greater SCr elevation, whereas sacubitril/valsartan use was associated with smaller relative SCr increases. In Firth logistic regression analysis, higher loop-diuretic dose was independently associated with AKI, while sacubitril/valsartan use was not significantly associated with AKI.

Conclusions

Under triple whammy exposure, sacubitril/valsartan was associated with smaller early increases in SCr compared with valsartan, while diuretic intensity emerged as a consistent determinant of renal deterioration. Although causality cannot be established, these findings highlight the importance of volume management and support further prospective investigation.
.
在心力衰竭患者三重打击暴露下,沙比里尔/缬沙坦与缬沙坦的肾脏预后比较:一项回顾性观察研究
同时使用肾素-血管紧张素-醛固酮系统(RAAS)抑制剂、利尿剂和非甾体抗炎药(NSAIDs),被称为“三重打击(TW)”,增加急性肾损伤(AKI)的风险。Sacubitril/缬沙坦在心力衰竭人群中显示出良好的肾效;然而,它在三重打击下的影响仍不清楚。方法本研究为单中心回顾性观察性研究,纳入2013年5月至2024年7月新开非甾体抗炎药的心力衰竭患者,这些患者接受缬沙坦或苏比里尔/缬沙坦联合利尿剂治疗。比较两组患者服用非甾体抗炎药后30天内血清肌酐(SCr)的变化。采用多变量线性回归来确定相对SCr变化的决定因素。与AKI相关的因素,定义为SCr增加≥0.3 mg/dL,使用多变量logistic回归与Firth的惩罚似然法进行评估,以解决稀疏事件计数。结果共纳入168例患者(缬沙坦71例,苏比里尔/缬沙坦97例)。sacubitril/缬沙坦组在基线时具有更高的利尿负荷。尽管如此,与缬沙坦组相比,SCr的相对增加明显较小。在多变量线性回归分析中,较高的环利尿剂当量剂量与较高的SCr升高独立相关,而使用苏比里尔/缬沙坦与较小的相对SCr升高相关。在第5次logistic回归分析中,较高的利尿剂剂量与AKI独立相关,而使用苏比里尔/缬沙坦与AKI无显著相关。结论:在三重打击下,与缬沙坦相比,苏比里尔/缬沙坦与早期SCr的增加较小相关,而利尿剂强度是肾脏恶化的一致决定因素。虽然不能确定因果关系,但这些发现强调了体积管理的重要性,并支持进一步的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nefrologia
Nefrologia 医学-泌尿学与肾脏学
CiteScore
3.40
自引率
7.70%
发文量
148
审稿时长
47 days
期刊介绍: Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书